Clavis Pharma announces the death of its Chief Medical Officer, Bo I. Nilsson
(Thomson Reuters ONE) -
Oslo, Norway, June 14, 2010
Clavis Pharma ASA (OSE: CLAVIS) announces the sad news that Bo I. Nilsson, its
Chief Medical Officer, died on 10 June following a long battle with cancer. Dr
Nilsson, aged 62, joined Clavis in May 2007.
Olav Hellebø, CEO, said: "Bo was a valued colleague and friend to the entire
Clavis Pharma family. He brought great knowledge and experience of cancer drug
development to Clavis from a long and successful career in the pharmaceutical
industry Dr. Nilsson has contributed greatly to the progress of our drug
pipeline and we hope that many other cancer patients will benefit from his
efforts in the future. It is with great sadness that we annouce his death. On
behalf of us all at Clavis, I would like to extend our deepest condolences to
Elsa and Bo's entire family."
For further information contact:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
+44 7833904901 (mob)
olav.hellebo(at)clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum(at)clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma(at)citigatedr.co.uk
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology drug development company based in
Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved versions of
commercially successful drugs, made using Clavis Pharma's Lipid Vector
Technology (LVT) chemistry. Data generated suggests these potential breakthrough
products may offer improved efficacy and reduced side effects through enhanced
pharmacokinetic properties, greater tissue penetration, altered metabolism and,
in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
· Elacytarabine, an improved form of Ara-C, a leukaemia drug - about to
commence a Phase III randomized, controlled registration study in late-stage
acute myeloid leukaemia;
· Intravenous CP-4126, an improved version of gemcitabine - currently in
a Phase II comparative study with gemcitabine for the treatment of pancreatic
cancer;
· CP-4200, an azacitidine derivative - in preclinical development for
myelodysplastic syndrome (MDS), often a precursor to myeloma or leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances
and partnerships with experienced oncology businesses and, where and when
commercially appropriate, by establishing its own sales and marketing
capabilities. CP-4126 is licensed to Clovis Oncology in the Americas and Europe.
Clavis Pharma has retained rights in other territories and an option to
co-promote CP-4126 in Europe.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker:
CLAVIS).
Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Clavis Pharma. There are a number
of factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
No expressed or implied representations or warranties are given concerning
Clavis Pharma or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient hereof by virtue of this
News Announcement or the information contained herein.
Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1423558]
Unternehmensinformation / Kurzprofil:
Datum: 14.06.2010 - 09:24 Uhr
Sprache: Deutsch
News-ID 22332
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma announces the death of its Chief Medical Officer, Bo I. Nilsson"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
